HIV感染者10年内进展为骨质疏松的高风险与概率:蛋白酶抑制剂的作用
该研究基于875例HIV感染者的3726次双能X线吸收检测,采用时间非齐次双向多状态模型分析骨密度进展。结果显示女性从骨量减少进展为骨质疏松的10年概率随年龄升高而显著增加,蛋白酶抑制剂(尤其是达芦那韦和阿扎那韦)与骨质疏松风险升高相关。作者认为应监测骨密度,并建议未来考虑更换替诺福韦以外的抗逆转录病毒药物如蛋白酶抑制剂以降低骨折风险。
要点
- 女性50岁时从骨量减少进展为骨质疏松的10年概率为30.1%,高于男性的19%。
- 男性使用达芦那韦者骨质疏松风险升高(HR 3.9),女性使用达芦那韦(HR 4.5)或阿扎那韦(HR 4.2)风险亦升高。
- 作者建议监测骨密度,并考虑更换替诺福韦以外的药物如蛋白酶抑制剂以降低骨折风险。
核心结论
- HIV感染者进展为骨量减少/骨质疏松的概率高,尤其女性,应监测骨密度。
- 作者建议未来考虑更换替诺福韦以外的抗逆转录病毒药物如蛋白酶抑制剂以降低骨折风险。
研究设计与样本
- 研究纳入至少接受2次双能X线吸收检测的875例HIV感染者,共3726次扫描。
- 采用基于正常骨密度、骨量减少和骨质疏松三状态的时间非齐次双向多状态模型分析骨密度进展与年龄及抗逆转录病毒使用的关联。
主要发现
- 年龄>45岁 versus ≤45岁从正常骨密度进展为骨量减少的HR:男性0.71(95%CI 0.45-1.11),女性1.06(95%CI 0.55-2.05)。
- 年龄>45岁 versus ≤45岁从骨量减少进展为骨质疏松的HR:男性0.83(95%CI 0.51-1.35),女性0.99(95%CI 0.38-2.56)。
- 30岁和50岁男性从骨量减少进展为骨质疏松的10年概率分别为14.9%(95%CI 10.5%-20.4%)和19%(95%CI 14.3%-24.3%)。
- 30岁和50岁女性从骨量减少进展为骨质疏松的10年概率分别为6.9%(95%CI 3.1%-14.4%)和30.1%(95%CI 19.8%-41.8%)。
- 达芦那韦与骨质疏松风险升高相关:男性HR 3.9(95%CI 2-7.5),女性HR 4.5(95%CI 1.4-14.7);阿扎那韦与女性骨质疏松风险升高相关(HR 4.2;95%CI 1.3-14)。
临床怎么用
- 作者认为应监测骨密度,尤其关注女性。
- 作者建议未来考虑更换替诺福韦以外的抗逆转录病毒药物如蛋白酶抑制剂以降低骨折风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osteoporotic fractures still remain very infrequent and physicians rarely evaluate bone health. We wanted to assess the magnitude of this problem in the near future by determining the risk and likelihood of progression to osteoporosis. METHODS: We estimated the risk of progression to osteopenia/osteoporosis among HIV-infected patients with at least 2 DXA scans (3726 scans from 875 patients). Time-non-homogeneous bidirectional multistate models based on three states (normal bone mineral density, osteopenia and osteoporosis) were used to model the progression of bone mineral density as a function of age and to study the association between the risk of bone loss and antiretroviral use. RESULTS: The HRs associated with age (>45 versus ≤45 years) were: (i) from normal bone mineral density to osteopenia, 0.71 (95% CI 0.45-1.11) for men and 1.06 (95% CI 0.55-2.05) for women; and (ii) from osteopenia to osteoporosis, 0.83 (95% CI 0.51-1.35) for men and 0.99 (95% CI 0.38-2.56) for women. The transition probabilities from osteopenia to osteoporosis over 10 years among men aged 30 and 50 years were 14.9% (95% CI 10.5%-20.4%) and 19% (95% CI 14.3%-24.3%), respectively; and for women, 6.9% (95% CI 3.1%-14.4%) and 30.1% (95% CI 19.8%-41.8%), respectively. An increased osteoporosis risk was observed for PIs and PIs + tenofovir disoproxil fumarate; darunavir was associated with a higher risk of osteoporosis among men (HR 3.9; 95% CI 2-7.5) and women (HR 4.5; 95% CI 1.4-14.7); and atazanavir was associated with a higher risk of osteoporosis among women (HR 4.2; 95% CI 1.3-14). CONCLUSIONS: Our results highlight the importance of monitoring bone mineral density given the high probability of progression to osteopenia/osteoporosis, especially in women. In the future, changes in antiretrovirals other than tenofovir, such as PIs, should be recommended to reduce the risk of fracture.
引用
- Negredo E, Langohr K, Bonjoch A, et al. High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. J Antimicrob Chemother. 2018. PMID: 29860519. doi:10.1093/jac/dky201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。